Cancer immunotherapy: Breakthrough or “deja vu, all over again”?
From the application of Coley’s toxin in the early 1900s to the present clinical trials using immune checkpoint regulatory inhibitors, the history of cancer immunotherapy has consisted of extremely high levels of enthusiasm after anecdotal case reports of enormous success, followed by decreasing lev...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IOS Press
2017-06-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317707764 |